Preclinical Dermatotoxicology Services for Antipsoriatic Drug Development
The development of safe and effective antipsoriatic drugs requires rigorous preclinical testing to assess potential dermatotoxic effects. Ace Therapeutics, a leading preclinical contract research organization (CRO), offers a comprehensive suite of dermatotoxicology services tailored to support the development of novel antipsoriatic therapeutics.
The Importance of Dermatotoxicology in Antipsoriatic Drug Development
Dermatotoxicology plays a critical role in antipsoriatic drug development, as skin safety is paramount for any topical treatment. Antipsoriatic drugs target the complex interplay between immune cells, inflammatory mediators, and keratinocyte proliferation in the skin. While these drugs are designed to alleviate the symptoms of psoriasis, they can also induce unintended dermatological effects. These effects can range from mild irritation to severe skin reactions. It is crucial to identify potential adverse effects, such as irritation, sensitization, or phototoxicity, that may result from skin exposure. In the preclinical phase of drug development, rigorous dermal toxicological assessments are crucial to ensure that new therapeutic candidates are safe for long-term use.
Fig. 1 Cytotoxicity analysis for reconstructed human epidermis based on MTT test. (Alicia Roso, et al., 2021)
Comprehensive Preclinical Dermatotoxicology Services for Antipsoriatic Drug Development
Ace Therapeutics offers a comprehensive suite of preclinical dermatotoxicology services designed to evaluate the safety of your antipsoriatic drug candidates. We provide the expertise and resources you need to navigate the complexities of dermatotoxicology studies.
Acute and Chronic Toxicity Testing
We conduct thorough assessments to evaluate both immediate and long-term toxicity effects of your drug candidates on the skin.
| Service Options | Descriptions |
| Single-dose acute toxicity studies | Our services focus on the effects of a single exposure to test drugs by applying them to reconstructed human epidermis (RHE) models. We assess endpoints such as skin irritation, erythema, and edema, using methods such as the MTT assay to measure cell viability and evaluate overall skin response. |
| Repeated-dose toxicity studies | We evaluate the effects of multiple exposures over an extended period, assessing parameters such as cumulative irritation, histopathological changes, and potential for sensitization in a controlled environment. |
Skin Irritation and Corrosion Testing
Ace Therapeutics provide a range of services to assess skin irritation and corrosion potential effectively. These in vitro tests are designed to evaluate the irritation potential of substances by measuring cell viability and assessing histological changes post-exposure.
- Irritation Testing: We perform irritation tests by exposing RHE models to various concentrations of test drugs. Cellular responses are analyzed using flow cytometry to evaluate apoptosis and necrosis, along with histological examinations to identify any histopathological changes.
- Corrosion Testing: Utilizing established protocols, we evaluate the potential of test drugs to cause skin corrosion. Our analysis focuses on the effects on RHE models, including pH changes, morphological assessments, and the integrity of the skin barrier following exposure.
Skin Sensitization Testing
Our skin sensitization testing services include various assays that evaluate the potential for allergic reactions.
| Service Options | Descriptions |
| Direct Peptide Reactivity Assay (DPRA) | We utilize this assay to determine the reactivity of test drugs with skin proteins, facilitating the classification of test drugs as sensitizers or non-sensitizers. |
| Gene Reporter Assays | Our gene reporter assays are designed to assess keratinocyte activation by utilizing luciferase reporter constructs. Through these assays, we quantitatively measure the activation of key signaling pathways involved in the skin response. |
| Human Cell Line Activation Test | Using monocytic cell lines, we evaluate the activation of dendritic cells by measuring the expression of surface markers such as CD54 and CD86. This approach provides insights into the immune sensitization potential of the test drugs. |
Cutaneous Photosensitivity and Phototoxicology Evaluation
Given the frequent exposure to sunlight using topical therapeutics, evaluating the cutaneous photosensitivity and phototoxicity of antipsoriatic drugs is crucial. We employ in vitro models to evaluate the phototoxic potential of test drugs when exposed to UV radiation. This includes assessing cellular responses and viability after treatment and light exposure, enabling a comprehensive evaluation of phototoxic risks.
Our Advantages in Preclinical Dermatotoxicology Services
Our team at Ace Therapeutics possesses extensive expertise in psoriasis and dermatotoxicology, providing rigorous safety evaluations.
We utilize advanced in vitro and in vivo models that accurately recapitulate human psoriasis for precise assessments.
We offer customized study designs and ongoing support to meet the unique needs of each client.
At Ace Therapeutics, we are dedicated to advancing the development of safe and effective antipsoriatic drugs through our specialized dermatotoxicology services. Our comprehensive services and commitment to excellence make us a trusted partner for companies and researchers seeking to advance their antipsoriatic drug development in the preclinical stage. Contact us today to learn more about our services and how we can help you achieve your research objectives.
Reference
- Alicia Roso, et al. In vitro Approach to Assess Local Tolerance of Ingredients Dedicated to Specific Topical Care Applications. Journal of Dermatology and Skin Science. 2021 Mar 22;3(1).